Eli Lilly Breaks Ground on $3.5 Billion Lehigh Valley Manufacturing Facility to Expand Production of Next-Generation Obesity Medicines
Eli Lilly and Company has officially broken ground on a new $3.5 billion pharmaceutical manufacturing facility in Pennsylvania’s Lehigh Valley, marking another major milestone in the company’s efforts to strengthen domestic medicine production and expand its U.S. manufacturing capabilities. Located in Fogelsville, Pennsylvania, the new facility will support the production of next-generation injectable medicines and delivery devices, including treatments being developed for obesity and related metabolic conditions.
The investment forms part of Lilly’s broader $50 billion commitment to expanding pharmaceutical manufacturing capacity across the United States. Since 2020, the company has announced plans for 10 new U.S. manufacturing sites, reflecting its strategy to increase production capabilities, strengthen supply chain reliability, and meet growing demand for innovative medicines.
The Lehigh Valley facility is one of four manufacturing sites within this expansion program dedicated to injectable medicines and medical devices. A key focus will be supporting the production of emerging obesity treatments, including retatrutide, Lilly’s investigational first-in-class triple hormone receptor agonist targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.
The company expects the facility to become operational by 2031. Once completed, it will create approximately 850 high-wage permanent positions and generate around 2,000 construction jobs during the development and commissioning phases. The project is also expected to contribute to Pennsylvania’s growing life sciences industry while supporting economic development and community initiatives throughout the Lehigh Valley.
$3.5 Billion Investment Supports Next-Generation Obesity Treatments
Lilly’s latest manufacturing investment comes as the pharmaceutical industry continues to experience significant growth in demand for innovative treatments targeting obesity, type 2 diabetes, and other metabolic disorders.
Obesity has become a major global public health challenge, affecting millions of people and increasing the risk of several serious health conditions, including cardiovascular disease, type 2 diabetes, and other metabolic complications. Advances in incretin-based therapies have created new opportunities for pharmaceutical companies to develop treatments that can improve weight management and metabolic health.
Retatrutide represents an important part of Lilly’s next-generation medicine development strategy. The investigational treatment is designed to activate three hormone receptors: GIP, GLP-1, and glucagon. By targeting these three pathways, the medicine is being developed with the potential to deliver additional metabolic benefits for people living with obesity and related conditions.
Unlike treatments that primarily target one or two hormone pathways, retatrutide combines activity across three distinct receptors. Lilly believes this approach could help expand treatment possibilities for patients who require additional options for weight management and metabolic disease.
The new Lehigh Valley manufacturing facility will provide additional production capacity to support the potential future supply requirements of retatrutide and other emerging injectable medicines as the company’s research and development programs advance.
Commenting on the groundbreaking, David A. Ricks, Chair and Chief Executive Officer of Lilly, highlighted the growing importance of obesity treatment innovation and the need to expand manufacturing infrastructure to support future patient demand.
Ricks stated that obesity remains one of the most significant health challenges of the current generation and that scientific advances in treatment development are progressing rapidly. He noted that retatrutide is among several next-generation medicines Lilly is developing for people living with obesity, type 2 diabetes, or both.
He added that the $3.5 billion investment will enable the company to manufacture these medicines in Pennsylvania, supporting patients across the United States and international markets.
Part of Lilly’s $50 Billion U.S. Manufacturing Expansion
The Lehigh Valley project represents an important component of Lilly’s long-term commitment to expanding pharmaceutical manufacturing operations in the United States.
Since 2020, the company has announced 10 new domestic manufacturing sites as part of its broader investment strategy. These facilities are designed to strengthen production capabilities across several areas, including active pharmaceutical ingredients (APIs), injectable medicines, medical devices, and genetic medicines.
The expansion reflects Lilly’s efforts to establish a more extensive and technologically advanced manufacturing network capable of supporting both existing commercial products and future pipeline medicines.
Of the 10 announced facilities, five are focused on producing active pharmaceutical ingredients. These sites include locations in Richmond, Virginia; Huntsville, Alabama; Houston, Texas; and two facilities in Lebanon, Indiana.
The two Indiana projects include the Lebanon API facility and the Lilly Medicine Foundry. The Medicine Foundry will also focus on developing new manufacturing methods and producing medicines for clinical trials, supporting the company’s ability to advance experimental treatments through clinical development.
Four facilities are dedicated to injectable medicine production and device manufacturing. These include locations in Research Triangle Park and Concord, North Carolina; Kenosha, Wisconsin; and the newly announced Lehigh Valley site in Pennsylvania.
The remaining facility, Lebanon Advanced Therapies in Indiana, will focus on genetic medicines, adding capabilities in an increasingly important area of biotechnology and advanced therapeutic development.
Together, these investments are intended to create a diversified domestic manufacturing network that can support a wide range of pharmaceutical products and emerging treatment technologies.
By increasing production capacity across multiple locations, Lilly aims to strengthen supply chain resilience, improve manufacturing flexibility, and support the reliable availability of medicines as demand increases.
Advanced Manufacturing Technologies to Improve Production Quality
The Lehigh Valley facility is expected to incorporate advanced manufacturing technologies and digitally integrated systems throughout its operations.
Lilly plans to use machine learning, artificial intelligence (AI), advanced data analytics, and digital automation to improve production efficiency, strengthen quality management, and support consistent manufacturing performance.
These technologies will be integrated into manufacturing processes to support what the company describes as right-first-time execution. This approach is intended to reduce production errors, streamline operational activities, and improve the consistency and reliability of medicine manufacturing.
The facility will combine specialized manufacturing equipment with advanced digital infrastructure to support monitoring, process optimization, and quality assurance.
According to Lilly, pharmaceutical manufacturing requires extensive quality controls before medicines can be released for distribution. Each production run undergoes more than 5,000 documented steps, while every individual unit is imaged and inspected more than 70 times to identify potential defects.
These procedures demonstrate the company’s emphasis on maintaining strict manufacturing standards and ensuring that products meet established quality requirements before reaching patients.
Edgardo Hernandez, Executive Vice President and President of Lilly Manufacturing Operations, emphasized the importance of maintaining high manufacturing quality while incorporating advanced technologies into the company’s expanding production network.
Hernandez explained that Lilly’s manufacturing operations involve thousands of documented procedures and multiple inspection processes designed to protect patients and ensure product quality.
He noted that the Lehigh Valley facility will build on these established quality practices by introducing next-generation automation and digital systems.
According to Hernandez, integrating these technologies throughout the manufacturing environment will help improve operational consistency, support right-first-time execution, and strengthen the company’s ability to provide patients with reliable access to medicines produced in Pennsylvania.
The company’s approach highlights the growing role of digital transformation in pharmaceutical manufacturing, where automation, data integration, and advanced analytics are increasingly being used to improve productivity and maintain stringent quality standards.
Creating 850 Permanent Jobs and Approximately 2,000 Construction Opportunities
Beyond its pharmaceutical manufacturing objectives, the Lehigh Valley investment is expected to generate significant employment opportunities and support the regional economy.
Lilly anticipates that the new facility will create approximately 850 high-wage permanent positions once operational. These opportunities are expected to include a broad range of professional and technical roles, such as engineers, scientists, laboratory technicians, and manufacturing operations personnel.
The project is also expected to generate approximately 2,000 construction jobs as the facility is developed, built, and brought online.
The company has already begun hiring for positions in the Lehigh Valley and is encouraging qualified candidates to explore available career opportunities through its dedicated Lilly Lehigh Valley careers page.
In addition to immediate recruitment activities, interested professionals can join Lilly’s talent community to receive information about future employment opportunities as the project progresses.
The facility is expected to create demand for specialized skills in pharmaceutical production, engineering, laboratory operations, automation, and advanced manufacturing technologies.
The investment could also generate indirect economic benefits by supporting local suppliers, contractors, service providers, and other businesses connected to the pharmaceutical manufacturing ecosystem.
Pennsylvania Governor Josh Shapiro welcomed the announcement, describing the groundbreaking as another significant milestone for the state’s life sciences sector.
Shapiro said the investment demonstrates the strength of Pennsylvania’s workforce, research institutions, infrastructure, and resources. He emphasized that the project supports the administration’s objectives of encouraging innovation, strengthening the economy, and creating well-paying jobs throughout the Commonwealth.
He also highlighted the importance of maintaining an environment where scientific discoveries can translate into meaningful economic opportunities and improved outcomes for patients and families.
U.S. Senator Dave McCormick also welcomed Lilly’s investment, describing it as a major economic development achievement for Pennsylvania.
McCormick noted that the project will bring approximately 850 high-paying jobs to the region while strengthening American manufacturing and reinforcing Pennsylvania’s position as a leader in life sciences and innovation.
He added that attracting investments of this scale is an important part of building a business environment that supports economic growth and industrial development.
Lilly Commits Up to $1 Million to Support Lehigh Valley Communities
Alongside its manufacturing and employment commitments, Lilly is establishing a community partnership designed to support families and improve quality of life across the Lehigh Valley.
The company is working with the Upper Macungie Township Community Fund on an anticipated new community initiative at the Upper Macungie Community Center.
Under the proposed commitment, Lilly will provide up to $1 million over five years to the Upper Macungie Township Community Fund.
The funding will support the development of a new quality-of-life program for families in the Lehigh Valley, with an emphasis on nutrition, healthy living, access to fresh food, health resources, and community-based programming.
The initiative reflects Lilly’s intention to establish long-term relationships with the communities surrounding its manufacturing operations.
Access to nutritious food, health education, and local wellness resources can play an important role in improving community health. By supporting programs focused on these areas, the company aims to contribute to initiatives that help families make healthier lifestyle choices and access relevant resources.
The partnership is also intended to support local organizations and community activities that strengthen the region’s overall quality of life.
As Lilly establishes its presence in the Lehigh Valley, the company has emphasized that its responsibilities extend beyond building and operating a manufacturing facility. Its community engagement strategy is intended to create lasting relationships with local residents, organizations, and public institutions.
Jeff Fleischaker, Chairman of the Upper Macungie Township Board of Supervisors, welcomed Lilly’s arrival and expressed enthusiasm about the groundbreaking.
Fleischaker said the township’s Board of Supervisors, staff, and residents are pleased to welcome the company to the community. He also highlighted the opportunity for Lilly and local stakeholders to work together on initiatives that improve everyday life for residents.
The partnership with the Upper Macungie Township Community Fund represents an early example of how the company’s investment will extend into community development and local engagement.
Commitment to Environmental Sustainability
Lilly has also emphasized that the new manufacturing facility will be developed and operated according to high standards for safety, product quality, and environmental stewardship.
The company intends to pursue Leadership in Energy and Environmental Design (LEED) Gold certification for the Lehigh Valley facility.
LEED is a widely recognized green building certification program that evaluates buildings based on environmental performance and sustainability considerations.
The certification target reflects Lilly’s efforts to incorporate sustainable practices into its expanding manufacturing infrastructure.
As pharmaceutical companies increase production capacity to meet growing global demand, environmental considerations have become an important component of facility planning and operational management.
Lilly’s sustainability objectives for the Lehigh Valley project are intended to support responsible resource management while establishing an advanced manufacturing environment.
The company has stated that it is committed to being a responsible neighbor in the Lehigh Valley and across Pennsylvania, with safety, quality, and environmental performance forming important elements of the facility’s development and future operations.
Lehigh Valley Facility Expected to Become Operational by 2031
Located in Fogelsville, Pennsylvania, the new Lehigh Valley facility is expected to become operational by 2031.
Its development represents a significant investment in the future of pharmaceutical manufacturing, particularly as Lilly prepares to support potential demand for its next-generation obesity treatments and other injectable medicines.
The facility will combine advanced production technologies, digital automation, specialized expertise, and a skilled workforce to support the manufacturing of safe and high-quality medicines.
The project also reflects the growing importance of domestic pharmaceutical production as companies seek to strengthen supply chains and increase their ability to manufacture innovative treatments closer to major patient markets.
With its $3.5 billion commitment, Lilly is expanding its U.S. manufacturing footprint while supporting employment, regional economic development, and community health initiatives.
Strengthening Lilly’s Long-Term Manufacturing Strategy
The groundbreaking of the Lehigh Valley facility marks another important step in Lilly’s broader $50 billion U.S. manufacturing expansion.
The investment comes at a time when the company is advancing a pipeline of innovative medicines targeting obesity, type 2 diabetes, and other serious health conditions. Retatrutide, its investigational triple hormone receptor agonist, is among the next-generation treatments that could contribute to future manufacturing requirements if successfully developed and approved.
By investing in production infrastructure ahead of potential future demand, Lilly aims to establish the manufacturing capacity needed to support its growing portfolio of medicines.
The Lehigh Valley project also brings together several priorities, including pharmaceutical innovation, advanced manufacturing, workforce development, environmental sustainability, and community investment.
With approximately 850 permanent jobs, around 2,000 construction opportunities, and up to $1 million in planned community funding over five years, the project is expected to have a broad impact across the region.
As construction progresses toward the anticipated 2031 operational target, Lilly will continue building its domestic manufacturing network to support the production of current and future medicines.
The new Pennsylvania facility reinforces the company’s long-term strategy of expanding U.S. manufacturing capabilities, strengthening medicine supply reliability, and preparing for the next generation of pharmaceutical innovation.
About retatrutide
Retatrutide is an investigational, once-weekly, triple hormone receptor agonist. Retatrutide is a single molecule that activates the body’s receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Lilly is studying retatrutide in several Phase 3 clinical trials to evaluate its potential efficacy and safety in obesity and overweight with at least one weight-related medical problem, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular outcomes, and metabolic dysfunction-associated steatotic liver disease. Retatrutide is an investigational molecule that cannot be legally sold or marketed for human use.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects.
advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering INNOVATIVE clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.